Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 251 to 300 of 323

Guidance and quality standards awaiting development
Title	Type
Shared decision-making: practical guidance for health and social care professionals	Quality standard
Sibeprenlimab for treating IgA nephropathy [ID6604]	Technology appraisal guidance
Sleep disordered breathing	Quality standard
Social work interventions for adults with complex needs (including learning disabilities) and mental health needs	Quality standard
Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536]	Technology appraisal guidance
Somapacitan for treating growth failure caused by Turner syndrome in people 2 to 17 years [ID6621]	Technology appraisal guidance
Sonesitatug vedotin for previously treated metastatic claudin 18.2-positive gastric or gastro-oesophageal junction adenocarcinomar [ID6669]	Technology appraisal guidance
Sotagliflozin for treating type 2 diabetes [ID1657]	Technology appraisal guidance
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]	Technology appraisal guidance
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]	Technology appraisal guidance
STS101 for treating acute migraine [TSID11782]	Technology appraisal guidance
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]	Technology appraisal guidance
Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081	Technology appraisal guidance
Supporting independent living and preventing isolation in adults of working age with social care needs	Quality standard
Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment in people 12 years and over [ID6630]	Technology appraisal guidance
Surovatamig for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more lines of treatment [ID6631]	Technology appraisal guidance
Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673]	Technology appraisal guidance
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]	Technology appraisal guidance
Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]	Technology appraisal guidance
Talquetamab with pomalidomide or teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6629]	Technology appraisal guidance
TAR-200 with cetrelimab for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6658]	Technology appraisal guidance
Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]	Technology appraisal guidance
Technologies to improve detection of endometrial cancer	Health technology evaluation
Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6628]	Technology appraisal guidance
The Sonata Treatment - Transcervical Radiofrequency Fibroid Ablation using Intrauterine Ultrasound	Medical technologies guidance
Thyroid disease	Quality standard
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915]	Technology appraisal guidance
Tildrakizumab for treating active psoriatic arthritis [TSID12218]	Technology appraisal guidance
Timrepigene emparvovec for treating choroideremia [ID3916]	Technology appraisal guidance
Tinnitus	Quality standard
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]	Technology appraisal guidance
Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]	Technology appraisal guidance
Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217]	Technology appraisal guidance
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]	Technology appraisal guidance
Tislelizumab for untreated unresectable hepatocellular carcinoma [TSID10683]	Technology appraisal guidance
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]	Technology appraisal guidance
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]	Technology appraisal guidance
Tocilizumab for treating systemic sclerosis [ID1396]	Technology appraisal guidance
Transvaginal Ultrasound-Guided Radiofrequency Ablation (RFA) for Uterine Fibroids	Interventional procedures guidance
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer [ID6620]	Technology appraisal guidance
Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511]	Technology appraisal guidance
Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603]	Technology appraisal guidance
Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]	Technology appraisal guidance
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]	Technology appraisal guidance
Treprostinil diethanolamine for treating pulmonary arterial hypertension [TSID11772]	Technology appraisal guidance
Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]	Technology appraisal guidance
Troriluzole for spinocerebellar ataxia [ID6456]	Technology appraisal guidance
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]	Technology appraisal guidance
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [TSID11781]	Technology appraisal guidance
Upadacitinib for treating moderate to severe hidradenitis suppurativa in people 12 years and over [ID6666]	Technology appraisal guidance

Results per page

10
25
50
All